Miami, Florida – Global Stem Cells Group (GSCG), an international organization dedicated to advancing regenerative medicine, is pleased to announce what it expects will be the expansion of its CELLGENIC brand into the Dominican Republic. This development is viewed as an important step in GSCG’s broader efforts to make advanced biologics and physician training increasingly accessible across Latin America and the Caribbean.
A Strategic Expansion in the Caribbean
Through this agreement, CELLGENIC hopes to introduce its exosome products and mesenchymal stem cell (MSC) therapies to the Dominican Republic, with the expectation of gradually expanding its product line to include additional advanced cellular therapies. This initiative is also expected to be supported by education and certification programs for physicians, so that the use of regenerative medicine technologies may be carried out responsibly and in line with international best practices.
“We are hopeful that extending CELLGENIC’s presence into the Dominican Republic will represent another meaningful step toward our mission,” said Benito Novas, CEO of Global Stem Cells Group and founder of CELLGENIC. “Our aim is to provide physicians with access to promising biologics alongside educational opportunities. By working closely with our local partners, we expect to help create an environment where regenerative medicine may continue to grow in a safe and ethical way.”
Local Leadership and Collaboration
The rollout in the Dominican Republic will be guided by Dra. Patria González, CELLGENIC’s official representative in the country. Together with her partners, Dr. Faddis Will and Irma Sánchez, Dra. González will support the introduction of CELLGENIC products to the local market.
“After years of development, we are excited about the opportunity to bring CELLGENIC products to physicians and patients in the Dominican Republic,” said Dra. González. “We believe strongly in the potential of regenerative medicine and we hope that exosomes, MSCs, and other advanced therapeutics will become important tools in our local healthcare system. Our expectation is that this collaboration will allow us to do so in alignment with international standards.”
Education at the Core
In addition to product introduction, ISSCA—the educational division of GSCG—plans to organize certification programs to support physicians in their training and clinical application of these protocols.
“Beyond the products themselves, we hope to make education a central part of this initiative,” added Novas. “We expect that properly trained physicians will be able to evaluate and apply these therapies in ways that may benefit their patients.”
Looking Ahead
As part of this collaboration, CELLGENIC and ISSCA will support the upcoming ISSCA 2026 event in the Dominican Republic, scheduled for the first quarter of 2026. The event is anticipated to bring together international experts, local physicians, and healthcare leaders to discuss new opportunities for regenerative medicine in the Caribbean.
“We are hopeful that this partnership will open the door to innovation in our country,” added Irma Sánchez. “The Dominican Republic is not only a beautiful place but also a healthcare market that we believe is ready to explore these possibilities. We expect that physicians and patients alike will benefit from the knowledge and products introduced through this collaboration.”
About Global Stem Cells Group and CELLGENIC
Founded in 2010 and headquartered in Miami, USA, Global Stem Cells Group (GSCG) is a biotechnology consortium with a presence in more than 40 countries. The organization brings together clinical research, physician education, and biologics development under one umbrella.
Its flagship brand, CELLGENIC, offers a portfolio of regenerative medicine products—including exosomes, MSCs, and platelet-rich plasma kits—produced under rigorous quality protocols. Through ISSCA, its educational division, GSCG provides certification programs, workshops, and international conferences that are expected to support the responsible adoption of regenerative therapies.
Global Stem Cells Group is a subsidiary to our publicly traded company, Regenerative Medical Technology Group Inc., operating under the symbol RMTG.
More information:
www.stemcellsgroup.com | www.issca.us
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions, including those related to expansion efforts into the Dominican Republic. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
